Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 20.51% is 888% above its 3-year average of 2.08%, near the high end of its 3-year range (0.00%–20.51%).
394.20% above its 12-month average of 4.15%.
Reported quarterly gross margin; no daily interpolation. Q4 FY2025 (2025-12-31): 8.30%.
GROSS MARGIN
20.51%
GROSS MARGIN AVG TTM
4.15%
GROSS MARGIN AVG 3Y
2.08%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+394.20%
CURRENT VS 3Y AVG
+888.40%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-50.22%
vs the sector median at left
Zhengye Biotechnology Holding Limited
Market Cap
$52.60M
Gross Margin
20.51%
TTM Avg
4.15%
3Y Avg
2.08%
5Y Avg
N/A
Market Cap
$52.83M
Gross Margin
41.51%
TTM Avg
45.14%
3Y Avg
44.16%
5Y Avg
37.16%
Market Cap
$51.99M
Gross Margin
N/A
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
16.67%
Market Cap
$51.88M
Gross Margin
-29.12%
TTM Avg
13.64%
3Y Avg
-48.92%
5Y Avg
-105.92%
Market Cap
$53.70M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$51.19M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$51.12M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$54.14M
Gross Margin
44.89%
TTM Avg
72.44%
3Y Avg
36.22%
5Y Avg
57.48%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zhengye Biotechnology Holding Limited (ZYBT) | $52.60M | 20.51% | 4.15% | 2.08% | N/A |
| Spectral AI, Inc. (MDAI)vs › | $52.83M | 41.51% | 45.14% | 44.16% | 37.16% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.99M | N/A | 50.00% | 25.00% | 16.67% |
| ImageneBio Inc (IMA)vs › | $51.88M | -29.12% | 13.64% | -48.92% | -105.92% |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.70M | 0.00% | 0.00% | 0.00% | 0.00% |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | 0.00% | 0.00% | 0.00% | 0.00% |
| Tenax Therapeutics, Inc. (TENX)vs › | $51.19M | 0.00% | 0.00% | 0.00% | 0.00% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | 0.00% | 0.00% | 0.00% | 0.00% |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $54.14M | 44.89% | 72.44% | 36.22% | 57.48% |
| biote Corp. (BTMD)vs › | $50.28M | 71.46% | 70.99% | 69.42% | 67.35% |
Gross Margin
20.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 8.30% |
| 2025-09-30 | 8.30% |
| 2025-06-30 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-06-30 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-06-30 | 0.00% |
| 2022-12-31 | 0.00% |
